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Abstract
Glycogen, a branched polymer of glucose, is well known as a cellular reserve of metabolic energy 
and/or biosynthetic precursors. Besides glucose, however, glycogen contains small amounts of 
covalent phosphate, present as C2 and C3 phosphomonoesters. Current evidence suggests that the 
phosphate is introduced by the biosynthetic enzyme glycogen synthase as a rare alternative to its 
normal catalytic addition of glucose units. The phosphate can be removed by the laforin 
phosphatase, whose mutation causes a fatal myoclonus epilepsy called Lafora disease. The 
hypothesis is that glycogen phosphorylation can be considered a catalytic error and laforin a repair 
enzyme.
 1. Introduction
Glycogen synthase (EC 2.4.1.11) transfers glucose moieties from its substrate UDP-glucose 
to form α-1,4-glycosidic linkages at the growing, non-reducing ends of a glycogen molecule 
([1]; Fig. 1). The ideas presented in this article had their origins in recent work from my 
laboratory that is described in three papers [2–4]. We showed that glycogen synthase rarely 
incorporates the β-phosphate of UDP-glucose into glycogen [4]. We also showed that the 
phosphate could be released by the action of the laforin phosphatase [2]. The hypothesis to 
be explored is that the incorporation of phosphate into glycogen is a catalytic error and that 
laforin acts as a repair or damage control enzyme.
 2. Enzyme specificity and side-reactions
In organic chemistry, yields can be low and side reactions problematic. In nature, enzymes 
have evolved to accelerate chemical reactions so as to permit a coherent pattern of chemical 
interconversions, fast enough and accurate enough, to fulfill the needs of the cell [5]. The 
kinetic properties of enzymes ensure proper fluxes through complex metabolic networks. 
How good must an enzyme be, in terms of its specificity and its ability to avoid unwanted 
side reactions? This question needs to be elaborated before addressing the specifics of 
glycogen phosphorylation and the hypothesis formulated above.
Discussion of enzyme specificity is often directed at selectivity for substrates, the degree of 
promiscuity, and immediately distinction must be made between enzymes that have 
seemingly evolved to catalyze one particular reaction, of which glycogen synthase might be 
considered an example, and enzymes, such as cytochrome P450s [6] or alcohol 
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dehydrogenases [7] whose evolved function is to act on a variety of substrates. The latter 
enzymes are not promiscuous and rather are multispecific or broad-specificity enzymes [6]. 
It may be difficult or impossible to define unique physiological substrates and products. 
However, even enzymes viewed as having evolved to mediate a single reaction can be 
capable of catalyzing other interconversions. There is indeed a substantial literature on this 
concept of catalytic promiscuity which is by no means a rare phenomenon [6]. Such 
alternate reactions may even be physiologically significant, and maintained through 
evolution, or alternatively they can simply be incidental due to the chemistry of the catalysis. 
Enzymatic promiscuity is viewed as critical for the evolution of new activities.
In a cell, the promiscuous activity of an enzyme towards an alternate substrate can be 
considered a side reaction. Another example of a side reaction, more in keeping with 
experimental organic synthesis, would be the generation of alternative products from the 
same substrate. For example, many phosphokinase enzymes are capable of hydrolyzing their 
co-substrate, usually ATP, to generate ADP and inorganic phosphate [8]. Similarly, the 
glucosyltransferase glycogenin, whose function is to transfer glucose from UDP-glucose to 
form a priming oligosaccharide for glycogen synthesis, can hydrolyze its substrate UDP-
glucose to generate UDP and glucose [9]. As explained below, the introduction of phosphate 
into glycogen may fall into this category of side reaction.
 3. Catalytic errors
When is a side reaction an error? Semantics as well as science enter into answering this 
question. The idea of an “error” requires that there is a “correct” outcome. Much discussion 
of catalytic errors has addressed the biosynthesis of information-rich biopolymers, like DNA 
[10], RNA [11] and proteins [12], for which a “correct” product can be defined. Errors occur 
when an incongruent base or amino acid, not directed by the coding polymer, is 
incorporated. Such events can be considered promiscuous substrate selection, a side-
reaction, even though all three of these syntheses are mediated by especially complex 
enzymatic machines. For all three processes, sophisticated editing and/or repair mechanisms 
exist to improve the fidelity of polymer production. For DNA synthesis, the rationale is 
especially compelling: misincorporation of a base in DNA can change the genetic blue-print 
of the cell and would be perpetuated through cell division. Special mechanisms have evolved 
to ensure accuracy in DNA synthesis and elaborate repair processes also exist. In this 
example, most people would agree that production of a new DNA molecule not faithfully 
reproducing the sequence of the priming strand is indeed an error, that there is an 
identifiable “correct” reaction. Compared with errors in DNA, mistakes in the synthesis of 
individual RNA or protein molecules obviously have a less deleterious impact but, even so, 
mechanisms exist to minimize their occurrence. How does glycogen phosphorylation 
compare with such processes?
 4. Glycogen, glycogen phosphorylation and Lafora disease
Glycogen, a branched polymer of glucose, serves as a reservoir of glucose, synthesized in 
times of nutritional plenty for use in times of need [1]. Glycogen isolated from biological 
sources is polydisperse and does not have a unique structure. A popular model of the 
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glycogen molecule envisions successive tiers of chains with an average length of 13 glucose 
residues [13,14]. Internal chains would have on average two branch points while the 
outermost tier would consist of unbranched chains (Fig. 1). The bulk synthesis of glycogen 
requires the action of two enzymes, glycogen synthase, mentioned above, and the branching 
enzyme which introduces the α-1,6-glycosidic linkages that form the branch points. The 
structure of glycogen is dictated by the kinetic properties of these two enzymes but in a 
stochastic rather than a precise way – not every chain is 13 glucoses long and branch points 
are not necessarily in identical relative positions in every chain.
Thus, the synthesis of glycogen is profoundly different from the mechanism by which 
nucleic acids and proteins are assembled with a strict conservation of informational content. 
Can we then assert that there is a “correct” glycogen product? Obviously not in the same 
way as is possible for nucleic acids and proteins but a number of genetic diseases of 
glycogen metabolism are informative on this point. Though rare, mutations in several 
different genes cause a series of glycogen storage diseases or glycogenoses [15]. In some 
cases, aberrant glycogen structures are formed that contribute to the pathology of the 
disease. For example, mutations in the branching enzyme gene cause Andersen or adult 
polyglucosan body diseases in which, as could be predicted, the glycogen formed has fewer 
branches than normal, leading to a less soluble polymer (sometimes called polyglucosan) 
that forms insoluble deposits. It would seem reasonable to consider polyglucosan to be an 
imperfect or even incorrect product of the glycogen synthetic pathway.
The most important constituent of glycogen is glucose which of course underlies its 
metabolic function. Since the 1980s, however, it has been recognized that glycogen contains 
trace amounts of phosphate [16–18], 1 phosphate per 500 to 1500 glucoses in muscle 
glycogen [2,3]. In mice, this level of phosphorylation is invariant with age [3]. From 
analyses of rabbit muscle glycogen, the phosphate was found to exist as phosphomonoesters 
at C2 and C3 of glucose residues [4]. For many years, the origin and function of the 
phosphate was obscure. Recently, however, Tagliabracci et al. [4] reported that in vitro the 
normal biosynthetic enzyme, glycogen synthase, was capable of introducing phosphate that 
originated as the β-phosphate of its substrate UDP-glucose. Phosphate incorporation was 
infrequent compared with the normal addition of glucose residues, 1 phosphate for every 
~10,000 glucoses. It was proposed that phosphate was introduced as glucose-phosphate in a 
side reaction mediated by glycogen synthase, with concomitant formation of UMP rather 
than UDP. The reason for the disparity between the rate of phosphate incorporation by 
glycogen synthase and the steady state glycogen phosphorylation state is likely explained by 
the fact that individual glycogen molecules undergo multiple rounds of synthesis and 
degradation, and phosphate can accumulate. Phosphate content depends not only on the 
synthetic rate but also the relative rates of glucose and phosphate removal.
Worby et al. [19] first reported that the laforin phosphatase could hydrolyze phosphate from 
amylopectin, a branched polysaccharide from plant starch which has a similar chemical 
structure to glycogen and which contains C3 and C6 phosphomonoesters [20,21]. They were 
unable to demonstrate dephosphorylation of liver glycogen. Subsequently, Tagliabracci et al. 
[2] demonstrated release of the phosphate from muscle glycogen by laforin. Laforin is, by 
amino acid sequence, a member of the dual specificity family of protein phosphatases (DSP; 
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[22]). Laforin is also the only phosphatase in mammalian genomes that, in addition to a DSP 
domain, has an integral carbohydrate binding module, of the CBM20 subfamily [23]. 
Mutation of the CBM20 abolishes the ability of laforin to bind to and to dephosphorylate 
glycogen [2]. Laforin, which is encoded by the EPM2A gene, was first identified in 
connection with a neurological disorder called Lafora disease, a fatal progressive myoclonus 
epilepsy with typical onset in the teenage years [24–27]. Roughly half of the cases of Lafora 
disease result from mutations in the EPM2A gene. A characteristic of Lafora disease is the 
presence of insoluble deposits, called Lafora bodies, in many tissues, including muscle, 
liver, heart and brain. The major constituent of Lafora bodies is poorly branched glycogen, 
polyglucosan. In a mouse model of Lafora disease in which the Epm2a gene is disrupted, an 
increase in glycogen phosphorylation was observed, suggesting that laforin 
dephosphorylates glycogen also in vivo [2]. As the Epm2a−/− mice aged, the increased 
glycogen phosphate correlated with disturbances in glycogen structure, decreased branching 
frequency, and decreased solubility in water, paralleling the formation of Lafora bodies in 
the mice [3]. Increased phosphate content has also been reported in Lafora bodies from 
Lafora patients [28]. Not understood currently is the exact relationship between the 
increased glycogen phosphorylation and the decreased branching frequency. There is, 
though, an emerging sense that Lafora disease might be a type of glycogenosis.
 5. Is laforin a repair or damage control enzyme?
Excessive accumulation of phosphate in glycogen is associated with structurally malformed 
glycogen, and so perhaps the side reaction of glycogen synthase responsible for the 
introduction of phosphate can be considered a catalytic error. There is a parallel with errors 
in nucleic acid synthesis in that infrequent side reactions are involved. Interestingly, for 
glycogen synthase, the error rate of ~10−4 is within the range of 10−3–10−6 reported for 
single base substitutions by proofreading-defective DNA polymerases [10]. If 
hyperphosphorylated glycogen is an aberrant biosynthetic product, can the enzyme that 
normally limits glycogen phosphorylation be considered a repair enzyme? Certainly, the 
absence of laforin activity leads to a serious pathological outcome in the form of Lafora 
disease. The phosphorylation of glycogen, however, differs from the misincorporation of 
bases into nucleic acids acids in that normal glycogen contains a low level of phosphate. 
Phosphate removal by laforin in vivo is not 100% efficient and a basal level of glycogen 
phosphorylation appears to be tolerated. It is as though there is a phosphorylation threshold 
below which glycogen structure can remain in an acceptable range. Without laforin activity, 
though, the result is devastating and I would argue that laforin normally acts in a repair or 
damage control function.
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Fig. 1. 
Model of glycogen structure and polyglucosan formation. Glycogen is depicted as being 
composed of successive tiers of polyglucose chains of average length 13 residues. The inner 
B chains would have on average two branches while the outer A chains would be 
unbranched. Normal glycogen synthesis, mediated by glycogen synthase (GS) and 
branching enzyme (BE), adds glucose moieties from UDP-glucose to the non-reducing ends 
of the molecule and introduces the branchpoints (grey chains; upper arrow). In the proposed 
rare side reaction (lower arrow), glucose-phosphate is transferred instead of glucose with the 
formation of UMP. The accumulation of covalent phosphate in glycogen is normally 
opposed by the action of the laforin phosphatase (LF). In the absence of active laforin, as in 
Lafora disease, phosphate accumulates in the glycogen leading ultimately to structural 
disturbances, the formation of poorly branched polyglucosan and the insoluble deposits of 
Lafora bodies.
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